Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGD001 in iTTP and Other Thrombotic Microangiopathies
NCT07459114Phase 2Not yet recruiting
- Sponsor
- TargED Biopharmaceuticals
- Start
- Oct 2026
- Primary completion
- May 2028
- Modality
- scFv Fragments, Therapeutic Enzymes, Nanobodies (VHH)
01
Overview
A Phase 2 trial of TGD001 in immune thrombotic thrombocytopenic purpura (iTTP), thrombotic microangiopathy (TMA), sponsored by TargED Biopharmaceuticals. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
TGD001
03
Conditions
immune thrombotic thrombocytopenic purpura (iTTP)thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT07459114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459114.